期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 19, 期 10, 页码 1469-1472出版社
INFORMA HEALTHCARE
DOI: 10.1517/13543770903059281
关键词
allergy; asthma; PF-03526299; R-343; Syk kinase
The subject of this application is N(4)-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N(2)-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine xinafoate salt, as well as inhalant formulations of the salt and a process for the preparation of the salt. This salt is probably R-343, a Syk kinase inhibitor being developed under license by Pfizer, an inhaled formulation of which is in Phase I development for the treatment of asthma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据